Phaarmasia Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The Hyderabad-based pharmaceutical company filed the mandatory certificate for the quarter ended 31st March, 2026.

Regulatory Compliance Details

The compliance certificate was issued by Venture Capital and Corporate Investments Private Limited, serving as the company's Registrar and Share Transfer Agent. The certificate, dated 03rd April, 2026, addresses the requirements under Regulation 74(5) of SEBI regulations.

Dematerialization Compliance

The certificate confirms that Phaarmasia Limited has maintained compliance with dematerialization requirements during the quarter. According to the registrar's certification, securities received for dematerialization have been properly processed following established protocols.

Key compliance aspects covered include:

• Securities received for dematerialization have been mutilated and cancelled after due verification
• Depositories have been updated in company records as registered owners
• Processing completed within the mandatory 15-day period upon receipt of valid DRF and share certificates
• Details of securities furnished to relevant stock exchanges

Depository Partners

The certificate specifically mentions both major depositories in India:

• National Securities Depository Limited (NSDL)
• Central Depository Services (India) Limited (CDSL)

Both depositories have been updated in the company's records as registered owners, ensuring proper maintenance of investor records and seamless trading of dematerialized securities.

Corporate Communication

The filing was signed by Urvashi Bhatia, Company Secretary and Compliance Officer of Phaarmasia Limited (Membership No. ACS. 46877). The company has requested BSE Limited to acknowledge receipt of the compliance certificate and take it on record.

This quarterly filing demonstrates Phaarmasia Limited's commitment to maintaining regulatory compliance and ensuring proper handling of investor securities through established depository mechanisms.

Phaarmasia Limited has responded to a BSE surveillance inquiry regarding significant movement in its stock price, clarifying that the price changes appear to be market-driven with no undisclosed material information affecting the security.

Regulatory Compliance Confirmation

In response to BSE's email dated April 13, 2026, Phaarmasia Limited confirmed its adherence to regulatory requirements. The company stated it has been regularly complying with SEBI (LODR) Regulations, 2015, including Regulation 30 provisions for disclosure of material events.

Price Movement Assessment

The pharmaceutical company addressed the BSE's inquiry about recent price movements by providing a comprehensive assessment of potential factors. Phaarmasia noted that the communication from BSE referred to the "recent past" without specifying the exact period under consideration.

Key points from the company's assessment include:

• All price-sensitive information has been duly disclosed to the exchange
• No pending announcements that could impact stock price
• Movement appears purely market-driven
• General market conditions identified as primary factor

Company's Position on Transparency

Phaarmasia Limited emphasized its commitment to maintaining transparency in all dealings with regulatory authorities. Company Secretary and Compliance Officer Urvashi Bhatia, who signed the clarification, reiterated the company's dedication to prompt disclosure of material events.

The company assured stakeholders that it will continue to inform the exchange of any material events or information as required under applicable regulations. This response demonstrates the company's proactive approach to addressing regulatory inquiries and maintaining investor confidence.

Regulatory Framework Adherence

The clarification highlights Phaarmasia's systematic approach to regulatory compliance. The company confirmed that all events, information, and disclosures that may have a bearing on operations and performance have been communicated to the exchange in a timely manner.

This response to BSE surveillance reflects the company's understanding of its obligations under securities regulations and its commitment to maintaining market integrity through transparent communication.